L. Lespy

SR120819A, an orally‐active and selective neuropeptide Y Y1 receptor antagonist

F. Oury-Donat, J. Maffrand, G. Néliat, 1995, FEBS letters.

Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.

J. Herbert, J. Maffrand, G. Le Fur, 1991, The Journal of pharmacology and experimental therapeutics.

Protective effect of SR 27417, a novel PAF antagonist, on lethal anaphylactic and endotoxin-induced shock in mice.

J. Herbert, J. Maffrand, L. Lespy, 1991, European journal of pharmacology.

Protective effect of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig.

J. Herbert, J. Maffrand, A. Bernat, 1992, Journal of lipid mediators.

SR142948A is a potent antagonist of the cardiovascular effects of neurotensin.

J. Herbert, P. Schaeffer, A. Bernat, 1998, Journal of cardiovascular pharmacology.

Neurotensin induces the release of prostacyclin from human umbilical vein endothelial cells in vitro and increases plasma prostacyclin levels in the rat.

J. Herbert, P. Schaeffer, A. Bernat, 1997, European journal of pharmacology.

Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.

D. Gully, G. Néliat, G. Le Fur, 1993, European journal of pharmacology.

Effect of the neurotensin receptor antagonist SR48692 on rat blood pressure modulation by neurotensin.

D. Gully, M. Canton, W. Rostène, 1996, Life sciences.